ВАССЕЛЛИ, Джеймс (US),УИГГИНТОН, Джон Марк (US),БОНВИНИ, Эцио (US),КЁНИГ, Скотт (US)
申请号：
RU2018111529
公开号：
RU2018111529A
申请日:
2016.10.06
申请国别(地区):
RU
年份:
2019
代理人:
摘要：
The present invention is directed to a combination therapy involving the administration of a first molecule that specifically binds to human B7-H3 and a second molecule that that specifically binds to human PD-1 to a subject for the treatment of cancer and/or inflammation. The invention also concerns pharmaceutical compositions that comprise a first molecule that specifically binds to human B7-H3 and a second molecule that specifically binds to human PD-1 that are capable of mediating and more preferably enhancing, the activation of the immune system against cancer cells that are associated with any of a variety of human cancers. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases in recipient subjects.
